MANAGEMENT
Executive Officers and Directors
The following table sets forth, as of March 12, 2004,
information about our executive officers and directors:
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
Joseph K. Belanoff, M.D.
|
|
46
|
|
Chief Executive Officer and Director
|
Robert L. Roe, M.D.
|
|
63
|
|
President and Secretary
|
Fred Kurland
|
|
54
|
|
Chief Financial Officer
|
James N. Wilson
|
|
60
|
|
Chairman of the Board
|
Alan F. Schatzberg, M.D.
|
|
59
|
|
Director
|
David B. Singer
(1)(3)(4)
|
|
41
|
|
Director
|
G. Leonard Baker, Jr.
(2)
|
|
61
|
|
Director
|
Steven Kapp
(1)(4)
|
|
44
|
|
Director
|
Alix Marduel, M.D.
(2)(3)
|
|
46
|
|
Director
|
Joseph C. Cook, Jr.
(1)(3)
|
|
62
|
|
Director
|
(1)
|
Member of the audit committee
|
(2)
|
Member of the compensation committee
|
(3)
|
Member of the nominating and corporate governance committee
|
(4)
|
Mr. Singer is married to Mr. Kapps sister. There are no other family relationships
between directors or executive officers.
|
Joseph K. Belanoff, M.D.
is a co-founder and has served as a member of our board of directors and as our Chief Executive Officer since 1999. Dr. Belanoff is currently a faculty member and has held various positions in the Department
of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as the Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff received his B.A. from
Amherst College and his M.D. from Columbia Universitys College of Physicians & Surgeons.
Robert L. Roe, M.D.
joined us as President in October 2001. He has spent more than 25 years in the pharmaceutical and biotechnology industries.
From 1999 to 2001, Dr. Roe served as President and Chief Executive Officer of Allergenics, Inc. From 1996 to 1999, he was Executive Vice President, Chief Operating Officer and a director of Cytel Corporation. From 1995 to 1996, he was Executive Vice
President, Chief Operating Officer and a director of Chugai Biopharmaceuticals, Inc. From 1992 to 1995, Dr. Roe served as President of the Development Research Division and Senior Vice President of Syntex Corporation. Dr. Roe received his B.A. from
Stanford University and his M.D. from the University of California, San Francisco.
Fred Kurland
joined us as Chief Financial Officer in February 2004. Mr. Kurland served as Vice President and Chief Financial Officer of Genitope Corporation from 2002 until February 2004. From 1998 to 2002 he
served as Senior Vice President and Chief Financial Officer of Aviron, Inc. Mr. Kurland served as Vice President and Chief Financial Officer of Protein Design Labs, Inc. from 1996 to 1998. From 1995 to 1996, Mr. Kurland served as Vice President,
Chief Financial Officer and Secretary of Applied Immune Sciences, Inc. From 1991 to 1995, Mr. Kurland served as Vice President and Controller of Syntex Corporation. Mr. Kurland received his B.S. from Lehigh University and his J.D. and M.B.A. degrees
from the University of Chicago.
James N.
Wilson
has served as a director and as Chairman of our board of directors since 1999. From 1996 to 2001, Mr. Wilson was Chairman of the board of Amira Medical, Inc. and in 2001 was also Chief Executive Officer. From 1991 to 1994, Mr. Wilson was
Chief Operating Officer of Syntex Corporation. From 1989 to 1990, Mr. Wilson was Chief Executive Officer of Neurex Corporation and from 1982 to 1988, Mr. Wilson was Chief Executive Officer of LifeScan, Inc. Mr. Wilson received his B.A. and his
M.B.A. from the University of Arizona.
48
Alan F. Schatzberg, M.D.
is a co-founder and has served as a member of our board of directors
and as chairman of our Scientific Advisory Board since 1998. Since 1991, Dr. Schatzberg has been a Professor and the Chairman of the Department of Psychiatry and Behavioral Sciences at Stanford Universitys School of Medicine and is Past
President of the American College of Neuropsychopharmacology. He received his B.S. from New York University and his M.D. from New York University, School of Medicine.
David B. Singer
has served as a member of our board of directors since 1998. Since February 2004, Mr. Singer has
served as Chairman of the Board of Directors of Genome Therapeutics Corporation. From September 1998 to February 2004, Mr. Singer was Chairman and Chief Executive Officer of GeneSoft Pharmaceuticals, Inc. From 1996 to 1998, Mr. Singer was Senior
Vice President and Chief Financial Officer of Heartport, Inc. From 1992 to 1996, he was President and Chief Executive Office of Affymetrix, Inc. He currently serves on the board of Affymetrix, Inc. Mr. Singer received his B.A. from Yale University,
and his M.B.A. from Stanford University.
G.
Leonard Baker, Jr.
has served as a member of our board of directors since 1999. Since 1973, Mr. Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm. Mr. Baker currently serves on the
board of Praecis Pharmaceuticals Incorporated and the board of Therma-Wave, Inc., each of which is a publicly traded company, and a number of private companies. Mr. Baker received his B.A. from Yale University and his M.B.A. from Stanford
University.
Steven Kapp
has served as a member of
our board of directors since 2001. Since 1996, he has been a principal at Maverick Capital, a private investment partnership. From 1993 to 1996, he was founder and a General Partner of Longwood Partners, a private investment partnership. He received
his B.A. and his M.B.A. from the University of North Carolina.
Alix Marduel, M.D.
has served as a member of our board of directors since 2001. Since April 1997, she has been a managing director of Alta Partners, a venture capital firm. From 1990 to 1997, Dr. Marduel was a general partner at
Sofinnova, Inc., a venture capital firm. She currently serves as director of a number of private companies. Dr. Marduel received her M.D. from the University of Paris.
Joseph C. Cook, Jr.
has served as a member of our board of directors since 2002. Mr. Cook is chairman of the
board of directors of Amylin Pharmaceuticals, Inc. Mr. Cook served as Chief Executive Officer of Amylin Pharmaceuticals from 1998 to 2003. Mr. Cook is a founder and currently serves as chairman of the board of Microbia, Inc. Mr. Cook is an officer
of Mountain Ventures, Inc., and a founder of Clinical Products, Inc. and Mountain Group Capital, LLC. Mr. Cook retired as Group Vice President of Eli Lilly & Company in 1993 after more than 28 years of service. Mr. Cook received his B.S. from
the University of Tennessee.
Scientific Advisory Board
In 1998, we convened a scientific advisory board of individuals with
expertise in psychiatry, psychopharmacology and neuroendocrinology. The chairman of our scientific advisory board is Dr. Schatzberg, who is also a member of our board of directors.
As of March 12, 2004, the following persons are members of our scientific advisory board:
|
|
|
|
|
Member
|
|
University Affiliation
|
|
Professional
Concentration
|
Alan F. Schatzberg, M.D.
|
|
Stanford University
|
|
Psychiatry
|
Charles B. Nemeroff, M.D., Ph.D.
|
|
Emory University
|
|
Psychiatry
|
Bruce S. McEwen, Ph.D.
|
|
Rockefeller University
|
|
Neuroendocrinology
|
K. Ranga Rama Krishnan, M.D.
|
|
Duke University
|
|
Psychiatry
|
Edo Ronald de Kloet, M.D.
|
|
Leiden University (the Netherlands)
|
|
Neurobiology
|
Florian Holsboer, M.D., Ph.D.
|
|
Max Planck Institute of Psychiatry (Germany)
|
|
Psychiatry
|
Ned H. Kalin, M.D.
|
|
University of Wisconsin
|
|
Psychiatry
|
49
Scientific Advisory Board Compensation
We reimburse each member of our scientific advisory board for out-of-pocket expenses incurred in connection with attending
board meetings, but do not, except as described below, compensate them for their services as scientific advisory board members. In the past, with the exception of Dr. Schatzberg, we have granted options to purchase our common stock to each member of
our scientific advisory board. In August 1998, we granted to each of Dr. Nemeroff, Dr. McEwen, Dr. Krishnan, Dr. de Kloet and Dr. Holsboer an option to purchase 60,000 shares of our common stock at an exercise price of $0.00033 per share. In
April 2002, we granted to Dr. Kalin an option to purchase 25,000 shares of our common stock at an exercise price of $7.00 per share. Pursuant to a consulting agreement with us, Dr. Schatzberg received compensation of $60,000 as chair of the
scientific advisory board in 2002 and $60,000 for his services as chair in 2003. We can terminate this agreement for any reason upon 30 days notice to Dr. Schatzberg.
Board of Directors
We currently have eight directors.
The directors will be elected at each annual meeting of stockholders, or special meeting in lieu thereof. The authorized number of directors may be
changed only by resolution adopted by a majority of the board of directors.
Board Committees
Our board of directors has
established an audit committee, a compensation committee and a nominating and corporate governance committee.
Audit Committee
. Our audit committee consists of Messrs. Cook, Kapp and Singer. Our audit committee oversees our corporate
accounting and financial reporting process. Our audit committee evaluates the independent auditors qualifications, independence and performance; determines the engagement of the independent auditors; approves the retention of the independent
auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on the engagement team as required by law; reviews our financial statements; reviews our critical accounting policies and
estimates; and discusses with management and the independent auditors the results of the annual audit and the review of our quarterly financial statements. Mr. Singer will be our audit committee financial expert under the SEC rules implementing
Section 407 of the Sarbanes-Oxley Act of 2002. We believe that the composition of our audit committee meets the requirements for independence under the current requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules
and regulations. We believe that the functioning of our audit committee complies with the applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations. We intend to comply with future
requirements to the extent they become applicable to us.
Compensation Committee
. Our compensation committee consists of Dr. Marduel and Mr. Baker. Our compensation committee reviews and recommends policy relating to compensation and benefits of our officers and
employees, including reviewing and approving corporate goals and objectives relevant to compensation of the Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of those goals and objectives,
and setting compensation of these officers based on such evaluations. The compensation committee also administers the issuance of stock options and other awards under our equity incentive plan. We believe that the composition of our compensation
committee meets the requirements for independence under, and the functioning of our compensation committee complies with, any applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq National Market and SEC rules and regulations. We
intend to comply with future requirements to the extent they become applicable to us.
50
Nominating and Corporate Governance Committee
. Our nominating and
corporate governance committee consists of Dr. Marduel, Mr. Cook and Mr. Singer, each of whom is a non-management member of our board of directors. The nominating and corporate governance committee will identify and evaluate nominees for
election as directors, and review and assess our code of ethics.
Compensation Committee Interlocks and Insider Participation
Prior to establishing the compensation committee, the board of directors as a whole made decisions relating to compensation of our executive officers. No member of the board of directors or the compensation committee
serves as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving as a member of our board of directors or compensation committee.